The Benefits of Targeted Therapy for BRAF V600E Mutations

V600BRAF V600E mutations can be targeted using the combinations of Dbrafineb, plus a MEK inhibitor like Cellumetinib or Trometinib. Traditional chemotherapy is off-label use because they're not FDA-approved for pediatrics. In medial blastoma and appendamoma, in all of those tumors, radiation is part of standard of care.